TABLE 1.
Clinical characteristics of the COVID-19 patients.
| Characteristic | Total | Mild disease (scores 1–3) | Moderate disease (scores 4–5) | Severe disease (scores 6–9) | p-value |
| (N = 115) | (N = 19) | (N = 37) | (N = 59) | ||
| Age, median (IQR) (years) | 68.0 (52.0–76.0) | 61.0 (40.0–73.0) | 71.0 (52.0–79.0) | 66.0 (53.0–76.0) | 0.305a |
| Male sex, n (%) | 73 (63.5) | 6 (31.6) | 24 (64.9) | 43 (72.9) | 0.032b |
| Overweight or obese, n (%) | 69 (65.7) | 7 (70.0) | 24 (66.7) | 38 (64.4) | 0.749b |
| Smoker, n (%) | 21 (19.8) | 2 (18.2) | 5 (13.9) | 14 (23.7) | 0.467b |
| Pneumonia SARS-CoV-2, n (%) | 84 (83.2) | 2 (25.0) | 24 (70.6) | 58 (98.3) | <0.001b |
| C-reactive protein, median (IQR) (mg/L) | 72.0 (28.3–158.9) | 32.2 (17.9–54.5) | 63.5 (11.5–115.6) | 96.8 (34,0–177.0) | 0.063a |
| Coexisting conditions, n (%) | |||||
| Diabetes | 45 (42.1) | 2 (16.7) | 14 (38.9) | 29 (49.2) | 0.099b |
| Hypertension | 67 (62.0) | 4 (33.3) | 27 (73.0) | 36 (61.0) | 0.811b |
| Chronic respiratory disease | 21 (19.6) | 2 (16.7) | 5 (13.9) | 14 (23.7) | 0.236b |
| Immunosuppression | 11 (10.9) | 1 (12.5) | 4 (11.8) | 6 (10.2) | 0.783b |
| Hematological-oncological disease | 9 (8.5) | 2 (16.7) | 3 (8.6) | 4 (6.8) | 0.479b |
| Medication history, n (%) | |||||
| Previous chronic therapy | 86 (86.9) | 8 (100.0) | 29 (87.9) | 49 (84.5) | 0.403b |
| Antibiotic therapy (last 6 months) | 42 (38.9) | 5 (41.7) | 17 (45.9) | 20 (33.9) | 0.243b |
Patients were classified in accordance with the WHO Clinical Progression Scale. This scale provides a measure of illness severity across a range from 0 (not infected with SARS-CoV-2) to 10 (dead). Patients were grouped into three categories: mild disease (scores 1–3), moderate disease (scores 4–5), and severe disease (scores 6–9). IQR, interquartile range aKruskal–Wallis test. bChi-square test. Bold values indicate statistical significance with a *p < 0.05.